Atezolizumab did not confer any benefits when added to SBRT in a phase 3 trial of patients with inoperable, early-stage NSCLC.

Small-cell lung cancer (SCLC) is one of the most lethal cancers, with patients diagnosed with extensive-stage small-cell lung cancer (ES-SCLC) experiencing a median survival of just 12 months after ...

Abbisko Therapeutics completes first patient dosing in registrational study of irpagratinib to treat treatment of hepatocellular carcinoma: Shanghai Tuesday, June 17, 2025, 18:00 ...

The FDA has accepted the application for lurbinectedin in combination with atezolizumab as first-line maintenance for ES-SCLC.

Beth Israel Deaconess Medical Center names Dr. Elizabeth Mittendorf as Chief of new Breast Surgery Division, joining the Department of Surgery this fall.

Atezolizumab plus mFOLFOX6 is a practice-changing and new standard treatment for patients with dMMR stage III colon cancer,” said Frank Sinicrope, MD.

Abbisko Therapeutics (HKEX Code: 02256) today announced that it has completed first patient dosing in a registrational study of irpagratinib, a self-developed and highly-selective small molecule FGFR4 ...

Regulatory action was based on data from the Phase III IMforte trial, which showed that Zepzelca plus Tecentriq significantly ...

This week in oncology has been marked by significant strides in targeted therapies, a re-evaluation of established treatment paradigms, and compelling evidence for the impact of lifestyle ...

The PD-L1 Inhibitors drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being ...

The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small ...

Brian P. Mulherin, MD, shares his key takeaways from the 2025 ASCO Annual Meeting, highlighting significant advancements in SCLC and the challenge of information overload at large conferences.